India, Feb. 3 -- Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the Phase 3 BREAKWATER study of BRAFTOVI (encorafenib) Combination Regimen.
BRAFTOVI in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) in patients with metastatic colorectal cancer or mCRC harboring a BRAF V600E mutation showed a statistically significant and clinically meaningful improvement in PFS.
PFS, one of the trial's dual primary endpoints, was assessed by blinded independent central review (BICR), compared to patients receiving chemotherapy with or without bevacizumab.
Further, the BRAFTOVI combination regimen demonstrated a statisti...